

alzchem group

AGILE SCIENCE PURE RESULTS

alzchem group

Q3 2026

ANDREAS NIEDERMAIER, CEO
ANDREAS LÖSLER, CFO

October 29, 2026

DISCLAIMER

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, Alzchem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA – ANALYST PRESENTATION Q3 2026

I. Executive Summary

II. Business and financial details

III. Back-Up

HIGHLIGHTS

Alzchem is on expected growth level and confirms outlook

Strong performance on group level:

+ 4% revenue growth

+ 8% EBITDA growth

Major growth expansions are progressing

- Creatin capacity expansion in Germany as scheduled
- U.S. Nitroguanidin plant with cost and planning optimization underway

Specialty Chemicals remains the key growth and earnings driver

Basics & Intermediates impacted by lower volumes

Nitroguanidine expansion in Germany reaches technical start-up

Carbide furnace successfully back into operation

Share buyback program successfully completed

New program to follow with € 20m volume

2026 Outlook confirmed – Alzchem on growth path

© Alzchem Group AG / October 2026

AGENDA – ANALYST PRESENTATION Q3 2026

I. Executive Summary

II. Business and financial details

III. Back-Up



NITRALZ®

Perlka® CALCIUM CYANAMIDE

CaD

BASICS & INTERMEDIATES


The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.

alzchem group


BASICS & INTERMEDIATES SEGMENT (in M€)

Sales and EBITDA development on expected level

SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q3	DELTA 01 - 09
Volume	- 17.8%	- 7.8%
Price	- 3.6%	- 1.9%
Currency	+ 0.2%	- 0.2%

COMMENTS

- Expected decline in revenue primarily due to lower sales volumes
- Ongoing weak demand in agriculture and continued price pressure from Asian competitors in the pharmaceutical industry
- Positive impact from metallurgical business due to improved economic situation in the steel industry
- EBITDA impacted by high electricity and raw material prices
- Inventories reduced significantly after planned stock build-up in 2025

© Alzchem Group AG / October 2026



CREAMINO Dormex® Bioselect® DYHARD® Creapure®

SPECIALTY CHEMICALS


The "Specialty Chemicals" segment produces and sells high-quality specialty chemical ingredients with strong growth perspectives.

alzchem group


SPECIALTY CHEMICALS SEGMENT (in M€)

Ingredients for Specialty Applications push Sales and EBITDA

SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q3	DELTA 01 - 09
Volume	+ 6.4%	+ 5.1%
Price	+ 5.9%	+ 6.9%
Currency	+ 0.9%	- 1.0%

COMMENTS

- Specialty Chemicals expected key growth driver with positive volume and price effects
- Sales increased by 11% to EUR 313m
- Main sustainable growth areas:
  - Human Nutrition,
  - Defense
  - Custom Manufacturing
- Creatine growth supported by last years capacity increase
- Sales development leads to EBITDA growth and EBITDA margin increase

© Alzchem Group AG / October 2026




OTHER & HOLDING


The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.


alzchem group


OTHER & HOLDING SEGMENT (in M€)

Regulated grid fees impact sales and result









COMMENTS

- Sales broadly stable year-on-year with slight decline driven by lower electricity grid fee pass-throughs
- Q3 revenue increased due to higher demand from chemical park customers and increased electricity grid fees
- EBITDA impacted by infrastructure modernization measures

© Alzchem Group AG / October 2026

FINANCIAL OVERVIEW

Strong full-year performance with growth in all KPI

Alzchem Group	Q3 2025	Q3 2026	qoq %	2025 1 - 9	2026 1 - 9	yoy %
SALES (in M€)	137.3	139.9	+1.9%	424.8	443.8	+4.5%
EBITDA (in M€)	29.7	28.7	-3.5%	86.2	93.2	+8.1%
EBITDA margin (in %)	21.7%	20.5%	-1.1pp	20.3%	21.0%	+0.7 pp
Earnings per Share (in €)	1.61	1.34	-17.0%	4.62	4.77	+3.2%

- Sales increased to EUR 444m, while EBITDA margin improved from 20.3% to 21.0%
- Volume and price increases as key drivers for positive sales trend
- Higher sales portion of specialty products combined with sustained cost discipline resulted in a substantial improvement in EBITDA and EBITDA margin
- Energy and raw material costs with volatile development – price increases are being rolled out
- Higher depreciation charges after commissioning of new facilities reflect the increased level of investment activity
- Net result and earnings per share follow strong operating performance, but impacted by deprecation and financial result

SALES ANALYSIS	DELTA Q3	DELTA 01 - 09
Volume	-1.5%	+1.0%
Price	+2.8%	+4.2%
Currency	+0.6%	-0.7%

© Alzchem Group AG / October 2026

BALANCE SHEET & CASHFLOW

Balance sheet total shows the current growth CAPEX projects

Balance sheet KPIs (T€)	31.12.2025	30.09.2026	Deviation	
Balance sheet total	617,679	673,711	56,032	9.1%
Inventories	116,004	104,581	- 11,423	-9.8%
Equity	258,231	280,590	22,359	8.7%
Equity ratio	41.8%	41.6%	-0.2 pp	
Liabilities to Banks	41,118	86,299	45,181	109.9%
Cash and cash equivalents	71,720	63,845	- 7,876	-11.0%
Net financial debt (-) / asset (+)	**30,602**	**- 22,455**	**- 53,057**	**-173.4%**

Cashflow KPIs (T€)	1 - 9 2025	1 - 9 2026	Deviation	
Operating Cashflow	115,497	97,387	- 18,111	-15.7%
Investing Cashflow	- 67,430	- 117,570	- 50,140	74.4%
Free Cashflow	**48,067**	**- 20,183**	**- 68,250**	**-142.0%**
Financial Cashflow	- 29,404	12,327	41,731	141.9%
Net increase in cash	**18,663**	**- 7,856**	**- 26,519**	**-142.1%**

COMMENTS

- Increase in balance sheet total resulting from increased CAPEX
- Inventories further reduced following the carbide furnace refurbishment
- Stable equity ratio despite increase in balance sheet total
- €6m reduced pension obligation as interest increased
- Adjusted for customer payments (-€ 44m), operating cash flow was significantly stronger than in the previous year
- Investing cash flow increased significantly year-on-year driven by growth in defense and human nutrition as well as the replacement of the carbide furnace.
- Free cash flow turned negative year-on-year driven by significantly higher growth investments
- Financial cashflow impacted by new financing structure, dividend payments and share buyback program

KPI impact of nitroguanidine expansion in total on balance sheet

in M€




© Alzchem Group AG / October 2026


OUTLOOK 2026 (in M€)

Ongoing growth in sales and EBITDA on expected level

SALES



EBITDA



to
ising

COMMENTS

Outlook for 2026 confirmed

Major assumptions are still valid

- Possible cost increases in energy and raw materials shall be passed through to customers
- No additional impact from the Iran conflict; long-term disruption of global supply chains is not included in the outlook

Sales Growth

- Growth solely coming from ingredients in segment Specialty Chemicals
- Basics & Intermediates: Sales remain slightly below previous year's level
- Organic growth, no acquisitions

EBITDA Growth

- Further increase in specialty chemical sales will increase EBITDA as well
- Volume and price increases support EBITDA

© Alzchem Group AG / October 2026

FINANCIAL CALENDAR

Upcoming dates*



OCT 29	2026	Quarterly Statement 3rd Quarter 2026
NOV 12-13	2026	Jefferies Roadshow, New York, Boston
NOV 23-24	2026	Deutsches Eigenkapitalforum, Frankfurt
NOV 26-27	2026	Berenberg Roadshow, Stockholm
DEC 1	2026	Berenberg European Conference, London
DEC 10	2026	MPCM Exclusive Company Evening, Frankfurt
FEB 25	2027	Annual Report 2026
MAR 4	2027	EU Opportunities Conference, London
MAR 23	2027	J.P. Morgan European Chemicals Forum, London
APR 29	2027	Quarterly Statement 1st Quarter 2027
MAY 5	2027	Annual General Meeting
MAY 27	2027	Berenberg European Conference, Manhattan
JUL 29	2027	Half-year Financial Report 2027
OCT 28	2027	Quarterly Statement 3rd Quarter 2027


*subject to change

ALL DATES AT A GLANCE

Financial calender

FEEDBACK

We appreciate your feedback



Were your expectations met?

Are you missing any content?

WE APPRECIATE YOUR FEEDBACK!

Link

QR-Code

alzchem group

AGILE SCIENCE
PURE RESULTS

Investor Relations

T +49 8621 86-2888
F +49 8621 86-502888
ir@alzchem.com

AGENDA – ANALYST PRESENTATION Q3 2026

I. Executive Summary

II. Business and financial details

III. Back-Up

KPI IMPACT OF CUSTOMER GRANTS

Timing and effects on balance sheet and P&L

KPI EFFECTS
2025/2026

Cash / Assets	↑
Other receivables	↑
Equity	→
Contract liabilities	↑
Equity ratio	↓
Sales	→
EBITDA	→

KPI EFFECTS
2027 et seq.

Cash / Assets	→
Other receivables	↓
Equity	↑
Contract liabilities	↓
Equity ratio	↑
Sales	↑
EBITDA	↑


TOTAL EFFECTS in M€

Cash / Assets **69.9**

Other receivables **23.3**

93.2 Contract liabilities

EST KEY EFFECTS [1]



© Alzchem Group AG / October 2026

1) Only customer investment contribution / 2) Based on our current best estimate and ongoing negotiations

BALANCE SHEET

Alzchem Group


ALZCHEM GROUP (IN T€)	31.12.2025	30.09.2026	Deviation	
Intangible assets	3,530	4,018	489	13.8%
Tangible assets	276,980	353,611	76,631	27.7%
Investment properties				
Right of use (assets)	2,992	1,767	-1,224	-40.9%
Investments accounted for using the equity method				
Financials assets	6	6		
Trade receivables				
Other receivables	21,801	13,359	-8,441	-38.7%
there of Deferred tax assets for pensions provisions				
Deferred tax assets	15,711	14,060	-1,651	-10.5%
SUM NON-CURRENT ASSETS	**321,019**	**386,821**	**65,802**	**20.5%**
Inventories	116,004	104,581	-11,423	-9.8%
Trade receivables	73,416	77,371	3,955	5.4%
Financial assets	0	0	0	-61.6%
Other receivables	35,201	40,928	5,727	16.3%
Income tax receivables	319	165	-154	-48.3%
Cash and cash equivalents	71,720	63,845	-7,876	-11.0%
Assets classified as held for sale				
Other assets				
SUM CURRENT ASSETS	**296,660**	**286,890**	**-9,770**	**-3.3%**
SUM ASSETS	**617,679**	**673,711**	**56,032**	**9.1%**

ALZCHEM GROUP (IN T€)	31.12.2025	30.09.2026	Deviation	
Share capital	101,763	101,763		
RETAINED EARNINGS (+) / LOSS (-)	**232,111**	**259,096**	**26,984**	**11.6%**
Other comprehensive income	-12,398	-7,111	5,287	-42.6%
Own shares	-4,111	-14,148	-10,036	244.1%
SHARE TO THE SHAREHOLDERS	**256,296**	**278,528**	**22,231**	**8.7%**
Non-controlling interests	1,934	2,063	128	6.6%
SUM EQUITY	**258,231**	**280,590**	**22,359**	**8.7%**
Provisions for pensions	88,239	81,971	-6,268	-7.1%
Other provisions	18,981	19,568	587	3.1%
Loans	34,750	76,875	42,125	121.2%
Finance lease liabilities	1,239	436	-803	-64.8%
Trade liabilities	14		-14	-100.0%
Contract liabilities	88,099	84,754	-3,345	-3.8%
Other liabilities	492	702	210	42.6%
Deferred tax liabilities	8,730	10,417	1,687	19.3%
SUM NON-CURRENT LIABILITIES	**240,543**	**274,722**	**34,179**	**14.2%**
Other provisions	7,190	5,021	-2,169	-30.2%
Loans	6,368	9,424	3,056	48.0%
Finance lease liabilities	1,874	1,424	-450	-24.0%
Finance liabilities		67	67	
Trade liabilities	51,726	44,355	-7,371	-14.2%
Contract liabilities	2,433	9,289	6,857	281.8%
Other liabilities	38,340	40,046	1,706	4.4%
Income tax liabilities	10,973	8,771	-2,202	-20.1%
SUM CURRENT LIABILITIES	**118,904**	**118,398**	**-506**	**-0.4%**
Sum EQUITY AND LIABILITIES	**617,679**	**673,711**	**56,032**	**9.1%**

© Alzchem Group AG / October 2026

PENSION ACCOUNTING (IFRS)

Alzchem Group (M€)



IN FINANCIAL STATEMENT	PENSION PROVISION 31.12.2025	SERVICE COSTS EBITDA (PERSONELL EXPENSES)	NET INTEREST COSTS FINANCIAL RESULT	PENSION PAYMENTS	PENSION REMEASURE-MENTS OCI	PENSION PROVISION 30.09.2026	DEFERRED TAX ASSETS	PENSION LIABILITY 30.09.2026
BALANCE SHEET		✓	✓	✓	✓		✓	
P&L		✓	✓				✓	
CASHFLOW				✓				

- Interest rates increased from 4.1% to 4.7%
- Pension payments develop as expected with 2.2 M€ - pension obligation has a long maturity with approx. 30 years payout period

© Alzchem Group AG / October 2026

INCOME STATEMENT

Alzchem Group

ALZCHEM GROUP (IN T€)	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026	Q4 2026	Deviation (Q3)	
Revenue	144,680	142,879	137,266	137,290	148,653	155,250	139,882		2,616	2%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	11,436	3,433	624	545	4,143	-11,145	-6,259		-6,882	<-1.000
Other income	5,263	5,006	3,806	9,266	7,339	6,038	6,349		2,542	67%
Raw materials and consumables used	-64,236	-47,293	-43,769	-42,989	-53,148	-39,986	-41,100		2,669	-6%
Employee benefits expense	-41,150	-44,894	-43,245	-44,322	-44,117	-47,660	-42,619		626	-1%
Other expense	-28,632	-30,036	-24,957	-29,494	-30,583	-30,297	-27,554		-2,597	10%
EBITDA	**27,362**	**29,096**	**29,724**	**30,296**	**32,286**	**32,199**	**28,698**		**-1,026**	**-3%**
Depreciation expense	-6,552	-6,435	-6,655	-7,007	-6,701	-7,494	-9,556		-2,901	44%
Impairment										
EBIT	**20,810**	**22,662**	**23,069**	**23,290**	**25,585**	**24,706**	**19,142**		**-3,927**	**-17%**
Investment income										
Other interest and similar income	712	626	819	1,082	381	175	929		110	13%
Other interest and similar expense	-1,278	-1,284	-1,254	-1,314	-1,330	-1,592	-1,523		-268	21%
Financial result	**-567**	**-658**	**-436**	**-232**	**-948**	**-1,417**	**-594**		**-158**	**36%**
Result from associates										
Result from ordinary business	**20,243**	**22,003**	**22,634**	**23,057**	**24,637**	**23,289**	**18,549**		**-4,085**	**-18%**
Taxes on income and profit	-5,607	-6,128	-6,297	-6,276	-6,636	-6,464	-5,002		1,295	-21%
thereof income tax	-4,537	-6,330	-5,550	-6,040	-5,754	-5,741	-4,846		*704*	*-13%*
thereof change from deferred taxes	-1,070	202	-748	-235	-882	-724	-156		*591*	*-79%*
Annual result	**14,636**	**15,876**	**16,337**	**16,782**	**18,001**	**16,825**	**13,547**		**-2,790**	**-17%**
thereof minority interests	43	43	43	43	43	43	43			
thereof shares held by shareholders	14,594	15,833	16,294	16,739	17,958	16,782	13,504		*-2,790*	*-17%*
Result per share in EUR	**1.44 €**	**1.57 €**	**1.61 €**	**1.66 €**	**1.77 €**	**1.66 €**	**1.34 €**			

© Alzchem Group AG / October 2026

INCOME STATEMENT

Alzchem Group

ALZCHEM GROUP (IN T€)	Q3 2025	Q3 2026	Deviation (QoQ)		YTD Sep.2025	YTD Sep.2026	Deviation (YoY)	
Revenue	137,266	139,882	2,616	1.9%	424,825	443,785	18,960	4.5%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	624	-6,259	-6,882	<-1.000%	15,493	-13,261	-28,754	-185.6%
Other income	3,806	6,349	2,542	66.8%	14,076	19,726	5,651	40.1%
Raw materials and consumables used	-43,769	-41,100	2,669	-6.1%	-155,297	-134,235	21,062	-13.6%
Employee benefits expense	-43,245	-42,619	626	-1.4%	-129,289	-134,397	-5,108	4.0%
Other expense	-24,957	-27,554	-2,597	10.4%	-83,625	-88,434	-4,810	5.8%
EBITDA	**29,724**	**28,698**	**-1,026**	**-3.5%**	**86,183**	**93,184**	**7,001**	**8.1%**
Depreciation expense	-6,655	-9,556	-2,901	43.6%	-19,642	-23,751	-4,109	20.9%
Impairment	0	0	0		0	0	0	
EBIT	**23,069**	**19,142**	**-3,927**	**-17.0%**	**66,541**	**69,433**	**2,892**	**4.3%**
Investment income	0	0	0		0	0	0	
Other interest and similar income	819	929	110	13.5%	2,156	1,485	-671	-31.1%
Other interest and similar expense	-1,254	-1,523	-268	21.4%	-3,817	-4,444	-627	16.4%
Financial result	**-436**	**-594**	**-158**	**36.3%**	**-1,660**	**-2,959**	**-1,298**	**78.2%**
Result from associates	0	0	0		0	0	0	
Result from ordinary business	**22,634**	**18,549**	**-4,085**	**-18.0%**	**64,880**	**66,474**	**1,594**	**2.5%**
Taxes on income and profit	-6,297	-5,002	1,295	-20.6%	-18,032	-18,102	-71	0.4%
thereof income tax	*-5,550*	*-4,846*	*704*	*-12.7%*	*-16,416*	*-16,340*	*76*	*-0.5%*
thereof change from deferred taxes	*-748*	*-156*	*591*	*-79.1%*	*-1,616*	*-1,762*	*-147*	*9.1%*
Annual result	**16,337**	**13,547**	**-2,790**	**-17.1%**	**46,849**	**48,372**	**1,523**	**3.3%**
thereof minority interests	*43*	*43*	*0*	*0.0%*	*128*	*128*	*0*	*0.0%*
thereof shares held by shareholders	*16,294*	*13,504*	*-2,790*	*-17.1%*	*46,720*	*48,244*	*1,523*	*3.3%*
Result per share in EUR	**1.61 €**	**1.34 €**	**0**	**-17.0%**	**4.62 €**	**4.77 €**	**0**	**3.2%**

© Alzchem Group AG / October 2026

CASHFLOW STATEMENT

Alzchem Group

CASHFLOW (IN M€)	Q3 2025	Q3 2026	1 - 9 2025	1 - 9 2026
Consolidated earnings before taxes	**22,634**	**18,549**	**64,880**	**66,474**
Depreciation on fixed and intangible assets	6,655	9,556	19,642	23,751
Decrease in pension provisions	-612	-671	-1,986	-2,160
Loss (+) / Profit (-) from the sale of non-current assets	-1	42	21	5
Other non-cash income (-) and expenses (+)	892	1,437	3,161	6,899
Financial result	436	594	1,660	2,959
Interests & Taxes	-4,556	-5,246	-12,442	-19,244
Increase (+) / Decrease (-) Net Working Capital	14,279	19,787	-14,977	7,275
Payments from customer grants		2,636	55,537	11,427
Cashflow from ongoing operations (Net cash flow)	**44,259**	**46,683**	**115,497**	**97,387**
Cash outflows for investments in fixed assets	-26,936	-36,430	-67,471	-117,735
Cash inflows from the sale of fixed assets	1	86	41	166
Cash inflows from grants received for investments				
Cashflow from investing activity	**-26,935**	**-36,344**	**-67,430**	**-117,570**
Free cashflow	**17,324**	**10,338**	**48,067**	**-20,183**
Deposits (+) of bank loans long-term				80,000
Repayment (-) of bank loans long-term	-1,583	-1,583	-6,000	-34,750
Deposits (+) / Repayment (-) from short-term financing lines				
Dividend payments			-18,190	-21,260
Payment of reduction in leasing liabilities	-482	-486	-1,438	-1,443
Payments for the acquisition of own shares (incl. transaction costs)	0	-10,043	-3,605	-10,043
Payments for the issue of own shares		0		-6
Payments to non-controlling interests			-171	-171
Cashflow from financing activity	**-2,065**	**-12,113**	**-29,404**	**12,327**

© Alzchem Group AG / October 2026

SEGMENT OVERVIEW BY QUARTER

Alzchem Group

SALES

SALES	2024 Q1 T€	2024 Q2 T€	2024 Q3 T€	2024 Q4 T€	2025 Q1 T€	2025 Q2 T€	2025 Q3 T€	2025 Q4 T€	2026 Q1 T€	2026 Q2 T€	2026 Q3 T€	2026 Q4 T€	Deviation PY (Q3) T€	Deviation PY (Q3) %	YTD Q3 2026 PY T€	YTD Q3 2026 Actual T€	Deviation PY (YOY) T€	Deviation PY (YOY) %
Basics & Intermediates	49,299	41,848	40,927	41,929	42,638	35,605	43,309	33,539	36,666	38,684	34,115		-9,194	-21%	121,552	109,465	-12,087	-10%
Specialty Chemicals	92,961	85,805	80,354	88,969	94,512	100,128	86,978	97,159	105,298	108,954	98,490		11,512	13%	281,617	312,742	31,124	11%
Other and Holding	7,804	8,538	7,656	8,142	7,530	7,146	6,979	6,592	6,689	7,611	7,277		298	4%	21,655	21,578	-77	0%
Group Consolidation																		
Alzchem Group	**150,064**	**136,191**	**128,937**	**139,040**	**144,680**	**142,879**	**137,266**	**137,290**	**148,653**	**155,250**	**139,882**		**2,616**	**2%**	**424,825**	**443,785**	**18,960**	**4%**

EBITDA

EBITDA	2024 Q1 T€	2024 Q2 T€	2024 Q3 T€	2024 Q4 T€	2025 Q1 T€	2025 Q2 T€	2025 Q3 T€	2025 Q4 T€	2026 Q1 T€	2026 Q2 T€	2026 Q3 T€	2026 Q4 T€	Deviation PY (Q3) T€	Deviation PY (Q3) %	YTD Q3 2026 PY T€	YTD Q3 2026 Actual T€	Deviation PY (YOY) T€	Deviation PY (YOY) %
Basics & Intermediates	1,802	3,055	1,827	4,142	140	1,174	3,754	549	284	-304	2,028		-1,727	-46%	5,068	2,008	-3,060	-60%
Specialty Chemicals	22,684	22,843	21,749	26,741	26,041	27,854	24,117	28,782	31,484	32,593	27,470		3,353	14%	78,012	91,548	13,536	17%
Other and Holding	537	849	1,114	-711	307	50	596	-287	222	-533	460		-136	-23%	954	148	-806	-84%
Group Consolidation	*-113*	*274*	*194*	*-1,717*	*874*	*18*	*1,257*	*1,253*	*296*	*443*	*-1,259*		*-2,516*	*-200%*	*2,149*	*-520*	*-2,669*	*-124%*
Alzchem Group	**24,910**	**27,021**	**24,883**	**28,455**	**27,362**	**29,096**	**29,724**	**30,296**	**32,286**	**32,199**	**28,698**		**-1,026**	**-3%**	**86,183**	**93,184**	**7,001**	**8%**

© Alzchem Group AG / October 2026

ALZCHEM GROUP LOCATIONS

Production sites and sales companies



Production facilities in Germany (4) and Sweden (1)
and HQ in Trostberg (GER)


© Alzchem Group AG / October 2026

“VERBUND” – FULLY INTEGRATED BUSINESS MODEL

Vertically integrated production of chemical products based on the NCN chain

Segment
Specialty Chemicals

Segment
Basics & Inter-
mediates



BENEFITS OF “VERBUND”

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

GLOBAL DEVELOPMENTS AS GROWTH DRIVERS

POPULATION GROWTH

LONGER LIFE EXPECTANCY

CLIMATE CHANGE

SUSTAINA-BILITY

SAFETY & DEFENCE

© Alzchem Group AG / October 2026

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries

	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO®	A nutritional additive for poultry and pigs	Feed additive
	Creapure®	Creapure®, premium brand for creatine monohydrate as ingredient in sports & health nutrition	Food supplements
	LIVA DUR	Dietary supplement with pure creatine	Food supplements
	Creavitalis®	Creatine for health and food applications	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREAK THRU S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Silzot HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder. paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
	Nitroguanidine	Intermediates for explosives and agrochemical products	Agriculture. Automotive. Defense

© Alzchem Group AG / October 2026

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries

	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES	CaD®	Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags. key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
	NITRALZ®	Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
	Eminex®	Reduction of methane emissions during storage of manure	Agriculture
	Perlka®	Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	Operation of the Trostberg Chemical Park (companies located at the site: Alzchem, BASF, Master Builders Solution, Sika, Firmenich, Klüh Catering, VIACTIV)		
	Site services		
	Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments		


© Alzchem Group AG / October 2026

KEY SHARE DATA

Share details as of October 27, 2026

SHARES OUTSTANDING	10,176,335
LAST CLOSING PRICE	EUR 161.60
MARKET CAPITALIZATION	EUR 1.644,5 m
TICKER	ACT
WKN	A2YNT3
ISIN	DE000A2YNT30
LISTING	Frankfurt Stock Exchange – Prime Standard
STOCK MARKET SEGMENT	SDAX
DESIGNATED SPONSOR	LBBW ODDO BHF SE

SHAREHOLDER STRUCTURE



As of June 2026: The information on the shareholders is based on the figures reported to us by them. Data regarding the free float are provided in accordance with section 5.8 of the Stoxx "DAX Equity Index Methodology Guide". The information is based on published notifications of major holdings. Certain reported positions may reflect bank holdings for trading or hedging purposes and are not separately presented above.

© Alzchem Group AG / October 2026